Author:
Yan Dan-Fang,Yan Sen-Xiang,Yang Jing-Song,Wang Yi-Xiang J,Sun Xiao-Li,Liao Xin-Biao,Liu Jun-Qing
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference24 articles.
1. Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000, 60: 15-23. 10.2165/00003495-200060001-00002.
2. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005, 366: 1527-37. 10.1016/S0140-6736(05)67625-8.
3. Niho S, Ichinose Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Jiang H, Nishiwaki Y, Fukuoka M: Results of a randomized phase iii study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. Proc Am Soc Clin Oncol. 2007, 25 (18S): [abstr LBA7509]
4. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008, 372: 1809-18. 10.1016/S0140-6736(08)61758-4.
5. Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim HY, Kim JH, Park SH, Lee KE, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K: Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res. 2004, 10: 4383-8. 10.1158/1078-0432.CCR-04-0189.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献